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Cholesterol synthesis is regulated by the transcription factor sterol regulatory element binding protein 2 (SREBP-2) and its target
gene 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is the rate-limiting enzyme in cholesterol synthesis.
Cyclic adenosine monophosphate–responsive element (CRE) binding protein–regulated transcription coactivator (CRTC) 2 is
the master regulator of glucose metabolism. However, the effect of CRTC2 on cholesterol and its potential molecular mechanism
remain unclear. Here, we demonstrated that CRTC2 expression and liver cholesterol content were increased in patients with high
serum cholesterol levels who underwent resection of liver hemangiomas, as well as in mice fed a 4% cholesterol diet. Mice with
adenovirus-mediated CRTC2 overexpression also showed elevated lipid levels in both serum and liver tissues. Intriguingly, hepatic
de novo cholesterol synthesis was markedly increased under these conditions. In contrast, CRTC2 ablation in mice fed a 4% cho-
lesterol diet (18 weeks) showed decreased lipid levels in serum and liver tissues compared with those in littermate wild-type mice.
The expression of lipogenic genes (SREBP-2 and HMGCR) was consistent with hepatic CRTC2 levels. In vivo imaging showed
enhanced adenovirus-mediated HMGCR-luciferase activity in adenovirus-mediated CRTC2 mouse livers; however, the activity
was attenuated after mutation of CRE or sterol regulatory element sequences in the HMGCR reporter construct. The effect of
CRTC2 on HMGCR in mouse livers was alleviated upon SREBP-2 knockdown. CRTC2 modulated SREBP-2 transcription by
CRE binding protein, which recognizes the half-site CRE sequence in the SREBP-2 promoter. CRTC2 reduced the nuclear pro-
tein expression of forkhead box O1 and subsequently increased SREBP-2 transcription by binding insulin response element 1,
rather than insulin response element 2, in the SREBP-2 promoter. Conclusion: CRTC2 regulates the transcription of SREBP-2
by interfering with the recognition of insulin response element 1 in the SREBP-2 promoter by forkhead box O1, thus inducing
SREBP-2/HMGCR signaling and subsequently facilitating hepatic cholesterol synthesis. (HEPATOLOGY 2017;66:481-497).
Cholesterol plays important roles in animal andcellular membranous structures and serves as aprecursor for steroid hormones and bile
acids.(1) In addition, it has been identiﬁed as a major
factor in the pathogenesis of atherosclerosis,(2) myocar-
dial infarction,(3) and strokes.(4) In mammals, both diet
and de novo biosynthesis are sources for cholesterol,(5)
and the liver is an important site for both the synthesis
and catabolism of cholesterol.(6)
3-Hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGCR) acts as the key rate-limiting enzyme in
cholesterol synthesis and the primary site of feedback
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regulation.(1) Several transcription factors, including
sterol regulatory element (SRE) binding protein 2
(SREBP-2), SREBP-1a, liver X receptor, and fork-
head box O (FoxO) transcription factors, have been
linked to cholesterol regulation in the liver.(7-13)
SREBP-2 is the master regulator of cholesterol synthe-
sis and can be regulated through transcriptional and
posttranscriptional mechanisms.(14) Moreover, FoxO1
modulates the transcription of SREBP-2.(12)
CRTC2 (also referred to as TORC2) is a member
of the cyclic adenosine monophosphate–responsive ele-
ment (CRE) binding protein (CREB)–regulated tran-
scription coactivator (CRTC) superfamily and has
been extensively studied in glucose homeostasis.(15,16)
In addition, CRTC2 is involved in modulating insulin
sensitivity,(17) endoplasmic reticulum stress,(18) virus
reactivation,(19) and obesity.(18) CRTC2 acts as a key
regulator in fasting glucose metabolism,(18) and studies
have suggested roles for CRTC2 also in triglyceride
homeostasis.(17,20,21) However, no in-depth study
regarding the role of CRTC2 on cholesterol metabo-
lism has been reported to date. This prompted us to
investigate whether CRTC2 affects cholesterol levels
in the liver, where CRTC2 is highly expressed.(21)
Through a series of studies in mouse and cellular
models, we demonstrated here that CRTC2 enhanced
SREBP-2 expression, resulting in elevated HMGCR
levels and cellular cholesterol synthesis. Remarkably,
CRTC2 inhibited the nuclear translocation of FoxO1
and reduced its binding to SREBP-2, resulting in an
increase in SREBP-2 transcription. Importantly,
knockdown of CRTC2 in mouse livers affected the
SREBP-2/HMGCR pathway. Thus, CRTC2 plays a
vital role in controlling hepatic cholesterol synthesis.
Materials and Methods
PATIENT TISSUE PREPARATION
Liver samples were obtained from 8 patients who
underwent surgical liver resection for liver hemangi-
oma. Each individual underwent serum testing before
surgery. We divided the patients into two groups
according to serum cholesterol levels(22): a low total
cholesterol group (Low-TC) and a high total choles-
terol group (High-TC). Patient liver tissues were biop-
sied at least 1 cm away from the lesions and conﬁrmed
as normal by at least one pathologist. Liver samples
were frozen in liquid nitrogen immediately after resec-
tion. None of the patients tested positive for hepatitis
B virus, hepatitis C virus, or human immunodeﬁciency
virus infection or were treated with a lipid-lowering
therapy. The study protocol was approved by the
Ethics Committee for Human Studies at the Shan-
dong Provincial Hospital. Written informed consent
was obtained from all patients before they entered the
study (see Table 1 for patient information).
ASSAY OF HEPATIC
CHOLESTEROL SYNTHESIS
Mice were fasted for 4 hours, intraperitoneally
injected with 10 lCi [1-14C]-sodium acetate (Perki-
nElmer, Waltham, MA), and euthanized 30 minutes
ARTICLE INFORMATION:
From the 1Department of Endocrinology, Shandong Provincial Hospital Afﬁliated to Shandong University; 2Shandong Clinical Medical
Center of Endocrinology and Metabolism; 3Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine; 4Scien-
tiﬁc Center, Shandong Provincial Hospital Afﬁliated to Shandong University; and 5Institute of Hepatobiliary Surgery, Shandong Academy
of Clinical Medicine, Jinan, Shandong, China; 6South Australian Health and Medical Research Institute, North Terrace; and 7School of
Biological Sciences, University of Adelaide, Adelaide, Australia; 8Department of Physiology and Neurobiology and The Institute for Sys-
tems Genomics, University of Connecticut, Storrs, CT; 9Veterans Affairs Connecticut Healthcare System, West Haven, CT; 10School of
Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China; 11Department of Internal Medicine, Section of Diges-
tive Diseases, Yale University, New Haven, CT.
ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Ling Gao, M.D., Ph.D.
Scientific Center, Shandong Provincial Hospital
Affiliated to Shandong University
Institute of Endocrinology, Shandong Academy of Clinical Medicine
544, Jing 4 Rd.
Jinan, Shandong, 250021, China
E-mail: gaoling1@medmail.com.cn
Tel: 186-13793187189
LI ET AL. HEPATOLOGY, August 2017
482
after injection. Then, hepatic cholesterol synthesis was
assayed as described.(23)
STATISTICAL ANALYSIS
The results are presented as means 6 standard devia-
tion for the number of experiments indicated. Statistical
signiﬁcance between two conditions was determined
using the Student t test, while one-way analysis of vari-
ance (Dunnett t or least signiﬁcant difference test) was
used for multiple comparisons. Data were analyzed
using SPSS 11.0 software. Differences were considered
signiﬁcant at P < 0.05.
Please see Supporting Information for more detailed
information of this section.
Results
HEPATIC CRTC2 EXPRESSION
IS INCREASED IN BOTH
PATIENTS WITH HIGH SERUM
CHOLESTEROL LEVELS AND
MICE FED A HIGH-
CHOLESTEROL DIET
We collected human liver samples from patients
undergoing surgical liver resection and divided them
into two groups according to the serum cholesterol lev-
els: Low-TC and High-TC. Subjects in the High-TC
group had higher low-density lipoprotein cholesterol
(LDL-C) levels, no obvious increases in the serum lev-
els of triglycerides (TG) and high-density lipoprotein
cholesterol (HDL-C) (Fig. 1A), and higher free total
cholesterol (FTC) and total cholesterol levels in the
liver (Fig. 1B); however, there was no difference in
hepatic TG between the two groups (Fig. 1B). The
High-TC patients also showed a marked increase in
the mRNA levels of CRTC2, SREBP-2, and
HMGCR (P < 0.01). By contrast, the gene expression
of SREBP-1a, liver X receptor, FoxO1, 3-hydroxy-3-
methylglutaryl-coenzyme A synthase (HMGCS), and
LDL receptor (LDLR) did not change appreciably
between the two groups (Fig. 1C).
Mice fed a high-cholesterol (HC) diet showed no
signiﬁcant changes in body weight (Fig. 2A, left).
However, the liver-to-body weight ratios (Fig. 2A,
right) and serum levels of glucose (Fig. 2B) and lipids
(Fig. 2C) were higher in mice fed the HC diet than in
mice fed the chow diet. The livers from mice fed the
HC diet showed increased fat accumulation as well as
higher FTC and total cholesterol contents (Fig. 2D).
Moreover, the hepatic mRNA and protein levels
of CRTC2 and phosphoenolpyruvate carboxykinase
(PEPCK, a downstream gene of CRTC2) were higher
in mice fed the HC diet (Fig. 2E,F). These results,
which were similar in the liver of patients and mice,
indicated that CRTC2 is related to cholesterol levels.
CRTC2 MODULATES
CHOLESTEROL BIOSYNTHESIS
IN VIVO AND IN VITRO
Mice with adenovirus-mediated CRTC2 overex-
pression (Ad-CRTC2) had higher CRTC2 mRNA
levels (Fig. 3A, left), body weight (Fig. 3A, middle),
and liver-to-body weight ratios (Fig. 3A, right) than
controls. Fasting blood glucose levels (Fig. 3B) and
impaired glucose tolerance (Fig. 3C) were also
increased. CRTC2 overexpression signiﬁcantly ele-
vated the serum total cholesterol levels (Fig. 3D, left).
Moreover, livers from mice overexpressing CRTC2
showed increased fat accumulation (Fig. 3D, right)
and FTC contents (Fig. 3E). An approximately 1.8-
fold increase in cholesterol levels was observed in the
HepG2 cells overexpressing CRTC2 compared with
the cells treated with the vector (Fig. 3F, left). Filipin
TABLE 1. Characteristics of Patients
Patients
Serum Total Cholesterol Levels
(mmol/L) Sex Age (Years) Pathological Diagnosis
Low-TC group
1 3.55 Male 61 Liver hemangiomas
2 2.87 Female 51 Liver hemangiomas
3 3.19 Male 68 Multiple liver hemangiomas
4 3.74 Female 57 Liver hemangiomas
High-TC group
5 7.45 Female 51 Liver hemangiomas
6 5.77 Male 60 Liver hemangiomas
7 5.39 Male 40 Liver hemangiomas
8 5.20 Female 63 Liver hemangiomas
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FIG. 1. Hepatic CRTC2 expression is increased in patients with high serum cholesterol levels. Lipid proﬁles in human serum (A)
and liver (B). Expression of cholesterol-related genes in human livers was measured using real-time PCR (C). All values are shown as
means 6 standard deviation (n 5 4). *P < 0.05 and **P < 0.01 versus the Low-TC group. Abbreviation: LXR, liver X receptor.
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FIG. 2. Hepatic CRTC2 expression is increased in mice fed an HC diet. C57BL/6J mice were fed a 4% cholesterol (HC) diet or a
chow diet for 20 weeks. (A) Comparison of body weight gain in mice (left, n 5 8-10) and liver-to-body weight ratios (right, n 5 6-
10). (B,C) Serum glucose and serum lipids levels (n 5 5-9). (D) Representative mouse liver sections stained with hematoxylin and
eosin (left); hepatic FTC and total cholesterol were measured (right) (n 5 5-8). (E,F) Hepatic mRNA and proteins were assessed.
CRTC2 and PEPCK were quantiﬁed and normalized to b-actin (n 5 3). *P < 0.05 and **P < 0.01 versus mice fed chow. Abbrevia-
tions: TC, cholesterol; TTC, total cholesterol.
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FIG. 3. Overexpression of CRTC2 elevates cholesterol levels in vivo and in vitro. (A-E) C57BL/6J mice were injected three times
(once every 5 days) with Ad-CRTC2 or Ad-GFP control through the tail vein. Mice were sacriﬁced for analysis 21 days after the ﬁrst
injection. (A) Real-time PCR analysis showing the mRNA of CRTC2 in mouse livers (left). Comparison of body weight gains (mid-
dle) and liver-to-body weight ratios (right) (n 5 6). (B) Blood glucose levels of mice fasted for 8 hours were measured (n 5 6). (C)
The oral glucose tolerance test was performed on mice (n 5 4-6). (D) Serum cholesterol, TG, HDL-C, and LDL-C were measured
(n 5 6, left). Representative mouse liver sections stained with hematoxylin and eosin (right). (E) FTC contents in liver tissues were
measured and corrected by the total protein content in the same sample (right, n 5 4). (F) HepG2 cells were transfected with an
empty vector or a Flag-CRTC2 overexpression plasmid for 48 hours. Then, cholesterol levels were measured. The amount of choles-
terol is expressed relative to that of the control cells (left) (n 5 3). The cellular distribution of free cholesterol was visualized with ﬁli-
pin staining (right). *P < 0.05 and **P < 0.01 versus Ad-GFP mice or vector. Abbreviations: OGTT, oral glucose tolerance test; TC,
cholesterol.
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staining, which is commonly used to visualize the cel-
lular distribution of free cholesterol,(24) showed
increased cholesterol accumulation in HepG2 cells
overexpressing CRTC2 (Fig. 3F, right). In contrast,
CRTC2 knockout mice (CRTC2–/–) (Fig. 4A) exhib-
ited lower fasting blood glucose concentrations and
glucose tolerance than wild-type (Wt) controls
(CRTC21/1) (Fig. 4B). Serum total cholesterol and
TG levels were also decreased (Fig. 4C), and the livers
of CRTC2–/– mice were smaller than those of
CRTC21/1 mice (Fig. 4D, left). Hematoxylin and
eosin staining showed reduced fat accumulation in the
hepatic intracellular vacuoles of CRTC2–/– mice (Fig.
4D, right). Hepatic FTC was also consistently reduced
(Fig. 4E, left). However, CRTC2–/– mice injected
with Ad-CRTC2 showed higher serum total choles-
terol levels (Fig. 4E, middle) and liver FTC contents
(Fig. 4E, right) than CRTC2–/– mice injected with
adenovirus-mediated green ﬂuorescent protein (Ad-
GFP). [1-14C]-Labeled sodium acetate was used to
assess de novo cholesterol synthesis.(22) Our results
showed that hepatic de novo cholesterol synthesis was
increased by approximately 2.0-fold in Ad-CRTC2
mouse livers (Fig. 4F), indicating that CRTC2 modu-
lates hepatic cholesterol synthesis.
CRTC2 MODULATES HEPATIC
HMGCR IN VIVO AND IN VITRO
Because CRTC2 induced an increase in cholesterol
synthesis (Fig. 4F) and because HMGCR is the key
rate-limiting enzyme in cholesterol synthesis,(25) we
tested whether CRTC2 could affect HMGCR expres-
sion. We found that CRTC2 overexpression signiﬁ-
cantly increased the mRNA levels of HMGCR,
farnesyl diphosphate synthase, squalene synthase,
adenosine triphosphate–binding cassette transporter A
1 (a gene involved in cholesterol export(26)), and the
gluconeogenic gene PEPCK in Ad-CRTC2 mouse
livers (Fig. 5A). However, the mRNA levels of cyto-
chrome P450 7A1 (the rate-limiting enzyme in bile
acid synthesis(27)) and acetyl-coenzyme A acetyltrans-
ferase 2 (ACAT2, a cholesterol-esterifying enzyme(26))
were reduced in the livers of Ad-CRTC2 mice, while
the LDLR levels were unchanged (Fig. 5A). Similarly,
CRTC2 overexpression consistently increased the
mRNA levels of HMGCR and glucogenic genes in
vitro (Fig. 5B). Moreover, in vivo imaging showed
that CRTC2 overexpression signiﬁcantly elevated the
luciferase activity of HMGCR-luciferase (Luc) in
mouse livers (Fig. 5C). In contrast, the expression of
genes related to cholesterol synthesis and uptake
(HMGCR, HMGCS, squalene synthase, and LDLR)
and other lipid transport genes (adenosine triphos-
phate–binding cassette transporter A 1 and ACAT2)
was reduced in CRTC2–/– mice (Fig. 5D). As in previ-
ous reports,(17) the gluconeogenic gene PEPCK was
also reduced in CRTC2–/– mouse livers (Fig. 5D).
CRTC2 overexpression consistently increased the pro-
tein levels of HMGCR in mouse livers (Fig. 5E),
whereas CRTC2 knockout reduced HMGCR protein
levels compared to the CRTC21/1 mice (Fig. 5F,
left). Similarly, CRTC2 small interfering RNA
(siRNA) reduced the expression of HMGCR in
HepG2 cells, as shown by immunoﬂuorescence (Fig.
5F, right). These results demonstrated that CRTC2
modulates hepatic HMGCR both in vivo and in vitro.
SREBP-2 IS INVOLVED IN THE
MECHANISM BY WHICH CRTC2
INCREASES HEPATIC HMGCR
Previous studies have reported that the HMGCR
promoter contains CRE and SRE sites, which can be
recognized by CREB and SREBP-2, respectively.(28)
We constructed a recombinant Luc reporter plasmid,
pGL4-HMGCR-Luc (Wt), containing the CRE
and SRE sequences and then mutated the CRE
(HMGCR-Luc [CRE-Mut]) or SRE (HMGCR-Luc
[SRE-Mut]) sequences (Fig. 6A). A signiﬁcant
increase of approximately 3.02-fold in the luciferase
activity of HMGCR-Luc (Wt) was detected after the
overexpression of CRTC2 (Fig. 6B); however, upon
mutation of the SRE binding site in the HMGCR
promoter (SRE-Mut), the effect of the CRTC2
overexpression from the resulting plasmid, HMGCR-
Luc (SRE-Mut), was reduced (Fig. 6B). Moreover,
HMGCR-Luc (CRE-Mut), with a mutated CRE
binding site, also resulted in reduced Luc activity (Fig.
6B). These data strongly indicated that SREBP-2 and
CREB are important for the role of CRTC2 in regu-
lating HMGCR transcription. Nevertheless, in this
study, we decided to focus on the modulatory role of
CRTC2 on SREBP-2.
SREBP-2 is a master regulator that controls the
transcription of critical genes involved in cholesterol
synthesis and uptake.(29) Thus, we examined the effect
of CRTC2 on HMGCR through SREBP-2. CRTC2
overexpression in mice markedly increased the mRNA
levels of SREBP-2 and both the precursor and mature
(nuclear) forms of SREBP-2 (SREBP-2 [P] and
SREBP-2 [N]) in mouse livers (Fig. 6C, left). Similar
HEPATOLOGY, Vol. 66, No. 2, 2017 LI ET AL.
487
                                                                                                                                      
FIG. 4. CRTC2 modulates hepatic cholesterol synthesis in vivo. (A-D) CRTC21/1 and CRTC2–/– mice were fed a diet containing
4% cholesterol ad libitum for 18 weeks. (A) PCR analysis showing CRTC2 fragments generated from Wt (CRTC21/1) or knockout
(CRTC2–/–) mice. (B) Blood glucose levels of mice fasted for 8 hours were measured (n 5 5). The oral glucose tolerance test was per-
formed on the mice (n 5 4-6). (C) Serum lipid proﬁles were measured (n 5 4-6). (D) Macroscopic pictures of mouse livers and rep-
resentative liver sections stained with hematoxylin and eosin. (E, left) FTC contents in the livers of CRTC21/1 and CRTC2–/– mice
fed a 4% cholesterol diet for 18 weeks (n 5 5-7 per group). (E, middle and right) Lipids in serum and liver tissues of CRTC2–/–
mice fed a 4% cholesterol diet and injected with adenovirus. (F) C57BL/6J mice were injected three times (once every 5 days) with
adenovirus for CRTC2 or GFP overexpression through the tail vein. Mice fasted for 4 hours were intraperitoneally injected with 10
lCi [1-14C]-sodium acetate and sacriﬁced 30 minutes after injection, and the livers were extracted for the analysis of de novo choles-
terol synthesis (n 5 3). *P < 0.05 and **P < 0.01 versus CRTC21/1 group or Ad-GFP group. Abbreviations: DPM, disintegrations
per minute; TC, cholesterol.
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FIG. 5. CRTC2 modulates hepatic HMGCR in vivo and in vitro. (A) Expression of cholesterol-related and gluconeogenic genes
was measured in livers from mice overexpressing Ad-CRTC2 or control Ad-GFP (n 5 3-6). *P < 0.05 and **P < 0.01 versus Ad-
GFP group. (B) HepG2 cells were transfected with an empty vector or an hemagglutinin–CRTC2 overexpression plasmid for 48
hours, and mRNA levels were measured. Data are from at least three independent experiments. **P < 0.01 versus vector. (C) Live
imaging of hepatic HMGCR-luciferase (Ad-HMGCR-Luc) activity in Ad-GFP or Ad-CRTC2-infected mice. (D) Expression of
cholesterol-related and gluconeogenic genes was measured in CRTC21/1 and CRTC2–/– mouse livers (n 5 3-6). **P < 0.01 versus
CRTC21/1 group. (E) Western blotting assays were used to evaluate CRTC2, HMGCR, and PEPCK protein expression in Ad-
GFP or Ad-CRTC2-infected mouse livers (E). (F) Western blotting assays were used to evaluate protein expression in CRTC21/1
and CRTC2–/– mouse livers (left). After transfection with nontargeting or CRTC2 siRNA for 48 hours, HepG2 cells were stained
for immunoﬂuorescence analysis. Blue indicates the DAPI-stained nuclei and red indicates the HMGCR protein (the secondary anti-
body was tetra methyl rhodamine isothiocyanate–conjugated) (right). Abbreviations: ABCA1, adenosine triphosphate–binding cassette
transporter A1; DAPI, 4,6-diamidino-2-phenylindole; FDPS, farnesyl diphosphate synthase; G6P, glucose 6-phosphate; NS, not sig-
niﬁcant; SS, squalene synthase.
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FIG. 6. CRTC2 increases hepatic HMGCR through SREBP-2. (A) The HMGCR reporter vectors containing CRE and SRE sequen-
ces, the mutated SRE (SRE-Mut), and the mutated CRE (CRE-Mut). (B) HEK293 cells were transfected for 48 hours with HMGCR-
luciferase constructs (Wt, SRE-Mut, or CRE-Mut) with or without control vector or a hemagglutinin–CRTC2 overexpression plasmid.
Luciferase activity was assayed in triplicate. (C) The mRNA and protein levels of SREBP-2 were tested in Ad-GFP and Ad-CRTC2
mouse livers (left) and HepG2 cells transfected with or without control vector or a hemagglutinin–CRTC2 overexpression plasmid for 48
hours (right). (D) Chinese hamster ovary cells were transfected with different doses of the indicated plasmids, and the protein levels were
assessed by western blotting using anti-Flag or antihemagglutinin antibodies. (E) The mRNA and protein levels of SREBP-2 were
assessed in CRTC21/1 and CRTC2–/– mouse livers. (F) C57BL/6J mice were injected three times (once every 5 days) through the tail
vein with adenoviruses overexpressing CRTC2 or GFP control and with or without lentivirus-mediated SREBP-2 silencing (Lv-SiS-
REBP-2) or nontargeting lentivirus (Lv-SiNS) (left). The mRNA and protein levels were measured by real-time PCR (middle) and west-
ern blotting assays (right). Precursor SREBP-2 (SREBP-2 [P]), mature (nuclear) SREBP-2 (SREBP-2 [N]). Each sample was analyzed
in triplicate, and samples from three different animals were analyzed to determine each value. In (C), the statistical signiﬁcance is relative
to Ad-GFP mice or vector, **P < 0.01. In (E), **P < 0.01 versus CRTC21/1 mice. In (F) *P < 0.05 and **P < 0.01 versus the Ad-
GFP1Lv-SiNS group. #P < 0.05 versus the Ad-CRTC21Lv-SiNS group. Abbreviation: HA, hemagglutinin.
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results were obtained in HepG2 cells overexpressing
CRTC2 (Fig. 6C, right). Furthermore, CRTC2 over-
expression in CHO-7 cells, which overexpressed Flag-
SREBP-2, markedly increased the proteolytic cleavage
of SREBP-2 in a dose-dependent manner, as shown
by elevated levels of the mature, nuclear form of
SREBP-2 (Flag-SREBP-2 [N]; Fig. 6D). Conversely,
in mouse livers, CRTC2 knockout decreased the
expression of SREBP-2 mRNA by approximately 60%
and both the precursor and mature forms of the pro-
tein (Fig. 6E).
Mice were injected with vectors for overexpression
of Ad-CRTC2 and lentivirus-mediated SREBP-2
silencing (Lv-SiSREBP-2) to further determine the
role of SREBP-2 in the CRTC2-induced regulation
of HMGCR (Fig. 6F, left). The results showed that
Lv-SiSREBP-2 not only reduced the gene expression
of HMGCR but also alleviated the increase in
HMGCR gene expression induced by CRTC2 overex-
pression (Fig. 6F, middle). A similar result was found
for HMGCR protein expression in Ad-CRTC2 and
Lv-SiSREBP-2 mouse livers (Fig. 6F, right).
CRTC2 REGULATES THE
TRANSCRIPTION OF SREBP-2
Previous reports have suggested that the promoter
sequence of SREBP-2 is recognized by several potential
transcription factors. In addition to the previously char-
acterized SRE(30) and insulin response elements (IRE1
and IRE2),(31) we found a CRE half-site (TGACG-
TAA) that can be recognized by CREB.(32) Thus, we
constructed pGL4.10-SREBP-2-Luc (Wt), a recombi-
nant luciferase reporter plasmid containing the CRE
and IRE sequences (Fig. 7A, upper), and then con-
structed the Ad-SREBP-2-Luc reporter. CRTC2
knockout reduced the Ad-SREBP-2-Luc activity in
mice (Fig. 7A, lower, left). Furthermore, chromatin
immunoprecipitation experiments demonstrated that
FoxO1 bound speciﬁcally to the SREBP-2 promoter.
CRTC2 signiﬁcantly reduced this binding (Fig. 7A,
lower, right). We used the transcription inhibitor acti-
nomycin D (Act-D) to further determine the transcrip-
tional effect of CRTC2 on SREBP-2. The results
showed that Act-D reduced the transcription of
SREBP-2. Similarly, the effect of CRTC2 on SREBP-
2 transcription was also inhibited by Act-D (Fig. 7B).
Thus, we explored the detailed mechanisms by which
CRTC2 can regulate SREBP-2 transcription.
We cloned the mutant CRE half-site in the mouse
SREBP-2 gene promoter (Fig. 7C, left) and showed
that the CRE mutation alleviated the effect of
CRTC2, although not completely (Fig. 7C, right).
This result indicated that CRTC2 might regulate the
SREBP-2 gene through other binding sites. FoxO1 is
activated after entry into the nucleus(33) and then nega-
tively regulates the transcription of SREBP-2 through
IREs.(12,31) We performed experiments using FoxO1
siRNA to conﬁrm these ﬁndings (Fig. 7D). Though
CRTC2 knockout had no effect on FoxO1 gene
expression (Fig. 7E, left), the levels of nuclear FoxO1
were increased in CRTC2 knockout mouse livers (Fig.
7E, middle). Similarly, though CRTC2 overexpression
did not change the mRNA levels of FoxO1 in hepato-
cytes, the levels of nuclear FoxO1 were decreased in
BNL cells and HepG2 cells (Fig. 7E, right). This
result is similar to those obtained in previous
reports.(34) Because there are two IRE sites, we sepa-
rately cloned mutant IRE1 and IRE2 in the mouse
SREBP-2 gene promoter to verify the role of CRTC2
in the regulation of the SREBP-2 gene through
FoxO1 (Fig. 7C, left). Compared with the Wt
reporter, CRTC2 overexpression signiﬁcantly inc-
reased the activity of the SREBP-2 promoter carrying
a mutation in IRE1; by contrast, IRE2 mutation was
not associated with notable changes (Fig. 7F).
CRTC2 REGULATES THE




Dietary absorption and biosynthesis are the two
sources for cholesterol acquisition in mammals.(5) We
analyzed whether CRTC2 affected lipid synthesis in
mice fed diets containing various amounts of choles-
terol. CRTC2 knockout mice were fed a diet with
0.02%, 1%, and 4% cholesterol. As expected, SREBP-
2 was strongly activated under low-cholesterol condi-
tions and decreased when CRTC21/1 mice were fed a
diet containing high cholesterol levels for 3 days (Fig.
8A). CRTC2 knockout greatly reduced SREBP acti-
vation in mice fed low-cholesterol diets (0.02% choles-
terol diet; Fig. 8A). However, CRTC2 knockout had a
minimal effect on SREBP-2 activation in mice fed a
4% cholesterol diet (Fig. 8A). CRTC2 knockout not
only strongly reduced the mRNA levels of SREBP-2
target genes (HMGCR, HMGCS, and LDLR) but
also ameliorated SREBP-2 gene expression at low cho-
lesterol levels (Fig. 8B). However, CRTC2 knockout
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FIG. 7. CRTC2 regulates the transcription of SREBP-2. (A) Schematic diagram of the proximal promoter of the mouse SREBP-2
gene; CRE and the two putative IREs (IRE1 and IRE2) are indicated (upper). Live imaging of hepatic SREBP-2-luciferase (Ad-
SREBP-2-Luc) activity in CRTC21/1 and CRTC2–/– mice fed an HC diet (lower, left). Chromatin immunoprecipitation assay his-
tograms representing the relative binding of FoxO1 to the SREBP-2 promoter in cells transfected with Flag-CRTC2 plasmids for 48
hours. The data were normalized to the corresponding immunoglobulin G (lower, right). (B) HepG2 cells were transfected with
empty vector or hemagglutinin–CRTC2 overexpression plasmids for 24 hours before actinomycin D (5 or 10 lg/mL) was added for 2
more hours; mRNA levels were then analyzed. (C) SREBP-2 reporter vectors containing the mutated CRE half-site (CRE-Mut),
mutated IRE1 (IRE1-Mut), or mutated IRE2 (IRE2-Mut) (left). HEK293 cells were transfected with a Flag-CRTC2 overexpression
plasmid or empty vector and SREBP-2-Luc (Wt) or SREBP-2-Luc (CRE-Mut) plasmids for 48 hours. Then, luciferase activity was
tested (right). (D) Real-time PCR was used to assess gene expression in HepG2 cells transfected with nontargeting (SiRNA-NC) or
FoxO1 siRNA (SiRNA-FoxO1) for 48 hours. (E) mRNA and protein expression levels in the cytoplasm and nuclei were examined in
CRTC21/1 and CRTC2–/– mouse livers (left). Real-time PCR for FoxO1 in BNL cells transfected with vector or a hemagglutinin–
CRTC2 overexpression plasmid for 48 hours (middle). Western blotting for nuclear FoxO1 in BNC cells and HepG2 cells (right).
(F) HEK293 cells were transfected with SREBP-2-luciferase constructs (Wt, IRE1-Mut, or IRE2-Mut), along with control vector or
a Flag-CRTC2 overexpression plasmid for 48 hours. Luciferase activity was assayed. Each sample was analyzed in triplicate, and sam-
ples from three different animals were analyzed to determine each value. In (B-F), *P < 0.05 versus “Vector1Act-D 5.0” or vector;
**P < 0.01 versus actinomycin D 5.0, siRNA NC, CRTC21/1 mice, or vector; ##P < 0.01 versus “Flag-CRTC21SREBP-2-Luc
(Wt).” Abbreviations: Acy D, actinomycin D; HA, hemagglutinin; IgG, immunoglobulin G.
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had a minimal effect on SREBP-2 function in mice
fed a 4% cholesterol diet (Fig. 8B). In addition, the
effects of CRTC2 knockout on the liver FTC and total
cholesterol levels were maximal at low cholesterol con-
centrations (Fig. 8C). Collectively, these data indicated
that CRTC2 exerts its effect on lipids under
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FIG. 8. CRTC2 regulates SREBP-2 activity in mice fed diets with varying amounts of cholesterol. (A-C) Seven-week-old male
CRTC2–/– mice and littermate CRTC21/1 mice were fed diets containing different cholesterol levels ad libitum for 3 days. Mice
were then sacriﬁced, and liver tissues were collected for analysis. Western blotting (A), mRNA (B), and lipid (C) analysis in mouse
livers (n 5 4). Lipid content was normalized by total protein content. *P < 0.05 and **P < 0.01 versus CRTC21/1 mice. (D) Sche-
matic diagram: CRTC2 activates SREBP-2/HMGCR signaling, resulting in hepatic cholesterol synthesis. CRTC2 inhibits nuclear
FoxO1 expression in the liver, blocking the negative effect of FoxO1 on SREBP-2 transcription by binding the IRE1 sequence
located in promoter of SREBP-2. Thus, the levels of the SREBP-2 precursor (P-SREBP-2) and mature (nuclear) SREBP-2 (N-
SREBP-2) increase. Mature SREBP-2 up-regulates the transcription of HMGCR by recognizing the SRE sequence in the HMGCR
promoter. In addition, CRTC2 promotes the proteolytic cleavage of the SREBP-2 precursor, yielding mature SREBP-2. Moreover, as
a coactivator of CREB, CRTC2 also increases the transcription of HMGCR by enhancing the effect of CREB on the CRE sequence
within the HMGCR promoter region. In this way, CRTC2 induces cholesterol synthesis. Abbreviation: TTC, total cholesterol.
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physiological conditions of low cholesterol, in which
cholesterol synthesis is required.
Discussion
In this study, we conﬁrmed that CRTC2 is a crucial
controller of cholesterol homeostasis. The expression
level of CRTC2 is important for the activities of liver
SREBP-2: CRTC2 overexpression stimulates SREBP-
2 activation, whereas CRTC2 knockout reduces
SREBP-2 activation. These changes are also accompa-
nied by changes in the expression of the SREBP-2 tar-
get genes HMGCR and LDLR. Furthermore, CRTC2
overexpression reduces the nuclear localization of
FoxO1, whereas CRTC2 knockout elevates it. Impor-
tantly, CRTC2 increases the transcription of SREBP-2
through FoxO1 recognition of the sequence of IRE1,
rather than IRE2, in the SREBP-2 promoter. There-
fore, CRTC2 plays an active role in hepatic cholesterol
synthesis by facilitating SREBP-2 transcription.
A key goal of this study was to determine whether
there is an association between CRTC2 and choles-
terol levels in the liver. The data from clinic samples
chosen in our study provided a positive, though indi-
rect, answer to this question. We employed various
tests to verify this ﬁnding in vivo and in vitro. CRTC2
overexpression in mice markedly increased cholesterol
levels in both the liver and serum, whereas the choles-
terol levels decreased in CRTC2 knockout mice. In
addition, CRTC2 initiated cholesterol synthesis, par-
ticularly in mice fed low-cholesterol diets. The amount
of cellular free cholesterol is dependent on the synthe-
sis and hydrolysis of cholesteryl ester.(35-37) The levels
of hepatic free cholesterol were increased in Ad-
CRTC2 mice and decreased in CRTC2 knockout
mice. [1-14C]-Labeled acetate is often used to assess de
novo cholesterol synthesis.(23) To further determine the
effect of CRTC2 on de novo cholesterol synthesis, we
injected [1-14C]-labeled acetate into Ad-CRTC2 mice
and veriﬁed that de novo cholesterol synthesis was ele-
vated in the liver.
The HMGCR gene promoter contains CRE and
SRE binding sites, which are the targets of the CREB
and SREBP-2 proteins, respectively.(27) CRTC2, a
coactivator of CREB, increases CREB activity follow-
ing its association with residues in the carboxy-
terminal basic Leu zipper domain of CREB.(38) How-
ever, mutation of CRE attenuated the activity of
HMGCR-Luc, though not completely. Importantly,
we observed a marked reduction in CRTC2-induced
HMGCR expression with HMGCR-Luc (mutation
of SRE) and with lentivirus-mediated knockdown of
SREBP-2. This result conﬁrmed that CRTC2 has
beneﬁcial effects on the transcription of HMGCR by
SREBP-2 over CREB.
SREBPs are regulated at the transcriptional level,
and they are also regulated by the proteolytic cleavage of
SREBP precursors and by the posttranslational modiﬁ-
cation of mature SREBP proteins.(39) Expression of the
precursor and mature nuclear forms of SREBP-2 in
mouse livers was shown to be dependent on CRTC2
levels. Furthermore, CRTC2 induced the activity of
SREBP-2-Luc in vivo and in vitro, prompting us to
focus on the transcription of SREBP-2. The mecha-
nism involved in this regulation remains unclear.
FoxO1 is currently considered an important factor con-
trolling SREBP-2 transcription.(12,40) A previous report
showed that the liver-speciﬁc deletion of FoxO1
induced a 60% increase in SREBP-2 mRNA, sugges-
ting that FoxO1 negatively regulates the transcription of
SREBP-2.(12) Similarly, we found that FoxO1 gene
silencing increased the transcription of SREBP-2. The
process of CRTC2-mediated SREBP-2 transcription
was associated with the decreased translocation of
FoxO1 into the nucleus. Tao et al. identiﬁed the IRE
(IRE1 and IRE2) sequences as the sites where the
FoxO1 protein binds to the SREBP-2 promoter.(31)
Intriguingly, in our model, CRTC2 performed its regu-
latory function on SREBP-2 transcription exclusively
through IRE1. Previous reports showed that CRTC2 is
a coactivator of CREB, which promotes the activity of
CREB through the CRTC2/CREB complex.(17)
CREB stimulates targeted gene expression at its pro-
moters that contain CREs. These typically appear as
either palindromic (TGACGTCA) or half-site
(TGACG or CGTCA) sequences.(32) In this study, we
also observed that CRTC2 regulated the transcription
of SREBP-2 through the CRE half-site located in the
SREBP-2 promoter. Thus, the mechanism of CRTC2
transcriptional regulation of SREBP-2 is complicated.
The regulation of posttranslational proteolysis is also
important for SREBP-2 activation.(41) We introduced
a model involving transfection with the exogenous full
SREBP-2 sequence(1) in combination with CRTC2
overexpression to conﬁrm whether CRTC2 also affects
the proteolysis of SREBP-2. We determined whether
there was a decrease in the precursor or an increase in
the mature form of SREBP-2, ﬁnding that CRTC2
modulates SREBP-2, at least to a certain extent, by
promoting proteolysis. Further investigation will
improve our understanding of this process.
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Previous reports have shown that CRTC2 has dif-
ferent effects on lipid metabolism under different con-
ditions.(20,34) For example, on a chow diet, the chronic
overexpression of CRTC2 activated CRTC2-induced
hepatic steatosis and higher levels of hepatic TG, as
expected in hyperglycemia.(33) After being fed a high-
fat diet (60% of calories from fat) for 12 weeks, liver-
speciﬁc CRTC2 siRNA mice showed reduced TG in
the liver and muscles as well as hyperglycemia.(20)
However, on the same diet for 18 weeks, CRTC2
knockout mice showed higher liver TG levels and
related gene expression but no notable changes in liver
cholesterol levels.(21) When we fed CRTC2 knockout
mice an HC diet (4% cholesterol) for 18 weeks, they
exhibited decreased serum TG levels and, in particular,
decreased cholesterol levels in the serum and liver.
Aside from the liver and muscle, CRTC2 also affected
adipocytes, including differentiated preadipocytes in
mice and the 3T3-L1 cell line,(42) in which ablation of
CRTC2 induced a decrease in the expression of TG-
related genes, such as SREBP-1C, fatty acid synthase,
and acetyl-coenzyme A carboxylase 1. Thus, CRTC2
is a coregulator of glucose, TG, and cholesterol metab-
olism, with different roles in different tissues, at differ-
ent feeding times, and with different diets.
Our study has some limitations. A previous study
showed that mice fed a high-fat diet exhibited an
increase in hepatic CRTC2 in a time-dependent man-
ner.(21) In addition, db/db and ob/ob mice exhibited
higher hepatic CRTC2 levels than lean mice.(21) The
current study provides evidence that clinical subjects
with elevated serum total cholesterol levels exhibit
higher levels of CRTC2 in the liver. This ﬁnding indi-
cated that CRTC2 is associated with cholesterol levels.
However, the analysis of human tissues did not permit
intervention experiments aimed at deﬁning the speciﬁc
role of CRTC2 in the accumulation of cholesterol or
the role of cholesterol in the increase of CRTC2
expression. Another limitation of this study was the
relatively small sample size of patients due to the difﬁ-
culty in obtaining liver specimens; therefore, we could
not analyze the relevance of CRTC2 and lipid levels in
humans. However, we included age-matched and sex-
matched patients with liver hemangiomas and
excluded patients with hepatitis B virus, hepatitis C
virus, or human immunodeﬁciency virus or those
receiving a lipid-lowering therapy. Thus, our data indi-
cated that in humans cholesterol levels are related, at
least partially, to CRTC2 expression in the liver. It
would be beneﬁcial to observe the effect of CRTC2 in
mice with CRTC2 liver-speciﬁc overexpression or
deletion. Nevertheless, we generated several in vivo
and in vitro models, including CRTC2 overexpression
or knockout mice and SREBP-2 knockdown mice, to
observe hepatic cholesterogenesis. Together with
marked changes in cholesterol levels and related gene
expression in mouse livers, we also observed changes in
the gene expression of adenosine triphosphate–binding
cassette transporter A1, cytochrome P450 7A1, and
ACAT2. These results suggested that CRTC2 may
also be involved in cholesterol efﬂux, conversion, and
esteriﬁcation. We also noted that the expression of
ACAT2 was similar in the livers of Ad-CRTC2 mice
and CRTC2–/– mice. It has been reported that hepato-
cyte nuclear factor 4a up-regulates the expression and
activity of ACAT2 in hepatocytes.(43) Our previous
study showed that SREBP-2 reduced the expression of
hepatocyte nuclear factor 4a in the liver.(27) In this
study, CRTC2 increased the expression of hepatic
SREBP-2. Thus, we suggest that the overexpression of
CRTC2 reduced the expression of ACAT2 by increas-
ing the levels of SREBP-2 in the liver. Furthermore,
FTC, LDL, and HDL also regulated the expression of
ACAT2 in hepatocytes.(44) FTC and LDL increased
the expression of ACAT2 in hepatocytes in a dose-
dependent manner. In contrast, HDL had the oppo-
site effect on ACAT2. Our results showed that Ad-
CRTC2 mice exhibited high hepatic FTC contents
and HDL and LDL-C levels in serum. CRTC2–/–
mice exhibited decreased hepatic FTC contents and
HDL-C and LDL-C levels in serum. Therefore, the
changes in ACAT2 in Ad-CRTC2 and CRTC2–/–
mice were comprehensive.
This study suggests a potential role for CRTC2 in
cholesterol homeostasis. Speciﬁcally, we revealed that
CRTC2 can act as a regulator by decreasing the levels
of nuclear FoxO1 in the liver, resulting in an increase
in SREBP-2 transcription and, consequently, up-
regulation of hepatic HMGCR and cholesterol syn-
thesis (Fig. 8D). Combined with previous reports on
the role of CRTC2 in the regulation of glucose, we
suggest that CRTC2 is a coregulator of both glucose
and lipid metabolism. These results might partially
explain the pathophysiological mechanisms of lipid
metabolism in diabetes.
Acknowledgment: We thank Dr. Yiguo Wang (MOE
Key Laboratory of Bioinformatics, Tsinghua-Peking
Center for Life Sciences, School of Life Sciences,
Tsinghua University, China) for providing the
CRTC2 knockout mice; Prof. Yi Liu and Prof. Yan
Chen (Key Laboratory of Nutrition and Metabolism,
HEPATOLOGY, Vol. 66, No. 2, 2017 LI ET AL.
495
Institute for Nutritional Sciences, Shanghai Institutes
for Biological Sciences, Chinese Academy of Scien-
ces, China) for providing the hemagglutinin–CRTC2
plasmids and Flag-SREBP-2 plasmids, respectively;
and Dr. Jeffery L. Meier (Division of Infectious Dis-
eases, University of Iowa Carver College of Medicine,
Iowa City, IA) for providing the Flag-CRTC2
plasmid.
REFERENCES
1) Xu D, Wang Z, Zhang Y, Jiang W, Pan Y, Song BL, et al.
PAQR3 modulates cholesterol homeostasis by anchoring Scap/
SREBP complex to the Golgi apparatus. Nat Commun 2015;6:
8100.
2) Pfrieger FW. Role of cholesterol in synapse formation and func-
tion. Biochim Biophys Acta 2003;1610:271-280.
3) Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R,
Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk
of myocardial infarction: a mendelian randomisation study. Lan-
cet 2012;380:572-580.
4) Curb JD, Abbott RD, Rodriguez BL, Masaki KH, Chen R,
Popper JS, et al. High density lipoprotein cholesterol and the
risk of stroke in elderly men: the Honolulu Heart Program. Am
J Epidemiol 2004;160:150-157.
5) Tanos R, Patel RD, Murray IA, Smith PB, Patterson AD,
Perdew GH. Aryl hydrocarbon receptor regulates the cholesterol
biosynthetic pathway in a dioxin response element-independent
manner. HEPATOLOGY 2012;55:1994-2004.
6) McIntyre N, Isselbacher KJ. Role of the small intestine in cho-
lesterol metabolism. Am J Clin Nutr 1973;26:647-656.
7) Sato R. Sterol metabolism and SREBP activation. Arch Biochem
Biophys 2010;501:177-181.
8) Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the
complete program of cholesterol and fatty acid synthesis in the
liver. J Clin Invest 2002;109:1125-1131.
9) Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W,
et al. Hepatic insulin resistance directly promotes formation of
cholesterol gallstones. Nat Med 2008;14:778-782.
10) Calkin AC, Tontonoz P. Transcriptional integration of metabo-
lism by the nuclear sterol-activated receptors LXR and FXR. Nat
Rev Mol Cell Biol 2012;13:213-224.
11) Wagner M, Zollner G, Trauner M. Nuclear receptors in liver
disease. HEPATOLOGY 2011;53:1023-1034.
12) Haeusler RA, Han S, Accili D. Hepatic FoxO1 ablation exacer-
bates lipid abnormalities during hyperglycemia. J Biol Chem
2010;285:26861-26868.
13) Zhang K, Li L, Qi Y, Zhu X, Gan B, DePinho RA, et al.
Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia
and hyperlipidemia in mice. Endocrinology 2012;153:631-646.
14) Krycer JR, Phan L, Brown AJ. A key regulator of cholesterol
homoeostasis, SREBP-2, can be targeted in prostate cancer cells
with natural products. Biochem J 2012;446:191-201.
15) Conkright MD, Canettieri G, Screaton R, Guzman E, Miraglia
L, Hogenesch JB, et al. TORCs: transducers of regulated CREB
activity. Mol Cell 2003;12:413-423.
16) Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S,
et al. The CREB coactivator TORC2 is a key regulator of fast-
ing glucose metabolism. Nature 2005;437:1109-1111.
17) Wang Y, Inoue H, Ravnskjaer K, Viste K, Miller N, Liu Y,
et al. Targeted disruption of the CREB coactivator Crtc2
increases insulin sensitivity. Proc Natl Acad Sci USA 2010;107:
3087-3092.
18) Wang Y, Vera L, Fischer WH, Montminy M. The CREB coac-
tivator CRTC2 links hepatic ER stress and fasting gluconeogen-
esis. Nature 2009;460:534-537.
19) Murata T, Sato Y, Nakayama S, Kudoh A, Iwahori S, Isomura
H, et al. TORC2, a coactivator of cAMP-response element-
binding protein, promotes Epstein-Barr virus reactivation from
latency through interaction with viral BZLF1 protein. J Biol
Chem 2009;284:8033-8041.
20) Saberi M, Bjelica D, Schenk S, Imamura T, Bandyopadhyay G,
Li P, et al. Novel liver-speciﬁc TORC2 siRNA corrects hyper-
glycemia in rodent models of type 2 diabetes. Am J Physiol
Endocrinol Metab 2009;297:E1137-E1146.
21) Han J, Li E, Chen L, Zhang Y, Wei F, Liu J, et al. The
CREB coactivator CRTC2 controls hepatic lipid metabolism by
regulating SREBP1. Nature 2015;524:243-246.
22) Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA,
Howard J, et al. Third report of the National Cholesterol Educa-
tion Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) ﬁnal report. Circulation 2002;106:314-323.
23) Li T, Matozel M, Boehme S, Kong B, Nilsson LM, Guo G,
et al. Overexpression of cholesterol 7alpha-hydroxylase promotes
hepatic bile acid synthesis and secretion and maintains cholesterol
homeostasis. HEPATOLOGY 2011;53:996-1006.
24) Gimpl G, Gehrig-Burger K. Cholesterol reporter molecules. Bio-
sci Rep 2007;27:335-358.
25) Hirayama T, Honda A, Matsuzaki Y, Miyazaki T, Ikegami T,
Doy M, et al. Hypercholesterolemia in rats with hepatomas:
increased oxysterols accelerate efﬂux but do not inhibit biosynthe-
sis of cholesterol. HEPATOLOGY 2006;44:602-611.
26) Calpe-Berdiel L, Escola-Gil JC, Blanco-Vaca F. New insights
into the molecular actions of plant sterols and stanols in choles-
terol metabolism. Atherosclerosis 2009;203:18-31.
27) Song Y, Xu C, Shao S, Liu J, Xing W, Xu J, et al. Thyroid-
stimulating hormone regulates hepatic bile acid homeostasis via
SREBP-2/HNF-4alpha/CYP7A1 axis. J Hepatol 2015;62:1171-
1179.
28) Di Croce L, Vicent GP, Pecci A, Bruscalupi G, Trentalance A,
Beato M. The promoter of the rat 3-hydroxy-3-methylglutaryl
coenzyme A reductase gene contains a tissue-speciﬁc estrogen-
responsive region. Mol Endocrinol 1999;13:1225-1236.
29) Ye J, Dave UP, Grishin NV, Goldstein JL, Brown MS. Aspara-
gine-proline sequence within membrane-spanning segment of
SREBP triggers intramembrane cleavage by site-2 protease. Proc
Natl Acad Sci USA 2000;97:5123-5128.
30) Sato R, Inoue J, Kawabe Y, Kodama T, Takano T, Maeda M.
Sterol-dependent transcriptional regulation of sterol regulatory
element-binding protein-2. J Biol Chem 1996;271:26461-26464.
31) Tao R, Xiong X, DePinho RA, Deng CX, Dong XC. Hepatic
SREBP-2 and cholesterol biosynthesis are regulated by FoxO3
and Sirt6. J Lipid Res 2013;54:2745-2753.
32) Altarejos JY, Montminy M. CREB and the CRTC co-activators:
sensors for hormonal and metabolic signals. Nature 2011;12:141-151.
33) Bastie CC, Nahle Z, McLoughlin T, Esser K, Zhang W,
Unterman T, et al. FoxO1 stimulates fatty acid uptake and oxi-
dation in muscle cells through CD36-dependent and -indepen-
dent mechanisms. J Biol Chem 2005;280:14222-14229.
34) Hogan MF, Ravnskjaer K, Matsumura S, Huising MO, Hull
RL, Kahn SE, et al. Hepatic insulin resistance following chronic
LI ET AL. HEPATOLOGY, August 2017
496
activation of the CREB coactivator CRTC2. J Biol Chem 2015;
290:25997-26006.
35) Mazzone T, Krishna M, Lange Y. Progesterone blocks intracel-
lular translocation of free cholesterol derived from cholesteryl
ester in macrophages. J Lipid Res 1995;36:544-551.
36) Reagan JW Jr, Hubbert ML, Shelness GS. Posttranslational reg-
ulation of acid sphingomyelinase in Niemann-Pick type C1
ﬁbroblasts and free cholesterol–enriched Chinese hamster ovary
cells. J Biol Chem 2000;275:38104-38110.
37) Kellner-Weibel G, Jerome WG, Small DM, Warner GJ,
Stoltenborg JK, Kearney MA, et al. Effects of intracellular free
cholesterol accumulation on macrophage viability: a model for
foam cell death. Arterioscler Thromb Vasc Biol 1998;18:423-
431.
38) Highland JA, Weiser MJ, Hinds LR, Spencer RL. CRTC2 acti-
vation in the suprachiasmatic nucleus, but not paraventricular
nucleus, varies in a diurnal fashion and increases with nighttime
light exposure. Am J Physiol Cell Physiol 2014;307:C611-C621.
39) Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F. SREBP
transcription factors: master regulators of lipid homeostasis. Bio-
chimie 2004;86:839-848.
40) Deng X, Zhang W, O’Sullivan I, Williams JB, Dong Q, Park
EA, et al. FoxO1 inhibits sterol regulatory element-binding pro-
tein-1c (SREBP-1c) gene expression via transcription factors Sp1
and SREBP-1c. J Biol Chem 2012;287:20132-20143.
41) Yellaturu CR, Deng X, Cagen LM, Wilcox HG, Mansbach CM
2nd, Siddiqi SA, et al. Insulin enhances post-translational proc-
essing of nascent SREBP-1c by promoting its phosphorylation
and association with COPII vesicles. J Biol Chem 2009;284:
7518-7532.
42) Park J, Yoon YS, Han HS, Kim YH, Ogawa Y, Park KG, et al.
SIK2 is critical in the regulation of lipid homeostasis and adipo-
genesis in vivo. Diabetes 2014;63:3659-3673.
43) Pramfalk C, Karlsson E, Groop L, Rudel LL, Angelin B,
Eriksson M, et al. Control of ACAT2 liver expression by
HNF4a lesson from MODY1 patients. Arterioscler Thromb
Vasc Biol 2009;29:1235-1241.
44) Pramfalk C, Angelin B, Eriksson M, Parini P. Cholesterol regu-
lates ACAT2 gene expression and enzyme activity in human hep-
atoma cells. Biochem Biophys Res Commun 2007;364:402-409.
Author names in bold designate shared co-ﬁrst
authorship.
Supporting Information
Additional Supporting Information may be found at
onlinelibrary.wiley.com/doi/10.1002/hep.29206/suppinfo.
HEPATOLOGY, Vol. 66, No. 2, 2017 LI ET AL.
497
